Investigations
Every investigation we've published, newest first — each one built on primary documents and classified under our evidence standard.
Fraud & Deception — 22 July 2024 — 7 min read
Sales calls and emails came in Spanish. The fine print came in English. The FTC says that gap was no accident — it was central to how the scheme kept borrowers from understanding what they'd signed up for.
Read the full report →
Fraud & Deception — 16 July 2024 — 6 min read
The DOJ charged Centurion Laboratories and its principals with submitting tens of millions in false Medicare claims for COVID-19 and respiratory pathogen panel tests purportedly ordered by physicians who never ordered them and patients who never received them.
Read the full report →
Institutions — 15 July 2024 — 7 min read
Evolent Health resolved allegations that inaccurate risk score submissions in its capitated care management programs inflated the per-member-per-month payments it received from health plans, resulting in systematic overbilling for the populations it managed.
Read the full report →
Institutions — 11 July 2024 — 7 min read
A DEA consent agreement with Rite Aid documented a pattern of dispensing controlled substance prescriptions without the pharmacist verification required to confirm legitimacy — failures that allowed opioid prescriptions showing clear red flags of diversion to be filled at the chain's pharmacies across multiple states.
Read the full report →
Corporations — 10 July 2024 — 6 min read
The SEC charged Epiq Systems, a legal services and technology company, with improper revenue recognition and misleading disclosures in financial statements that overstated the company's performance to investors across multiple fiscal years.
Read the full report →
Corporations — 8 July 2024 — 6 min read
The FTC investigated Safelite AutoGlass over its dual role as the country's largest auto glass repair provider and a major administrator of glass claims for insurance companies — a combination the agency examined for evidence that Safelite steered consumers toward its own repair network in ways that harmed competition and consumer choice.
Read the full report →
Corporations — 3 July 2024 — 7 min read
The SEC charged Align Technology with channel stuffing — shipping excess Invisalign aligner inventory to dental providers beyond actual demand to artificially inflate quarterly revenue figures — finding the practice constituted fraudulent revenue recognition that misled investors about the company's organic growth trajectory.
Read the full report →
Corporations — 3 July 2024 — 6 min read
Netsmart Technologies, the leading EHR vendor for behavioral health organizations, paid $1.75 million after a whistleblower documented a gap between the federal EHR certification the company claimed for its platform and the capabilities of the software as deployed to Medicaid-participating providers.
Read the full report →
Corporations — 30 June 2024 — 6 min read
The SEC charged SBA Communications, one of the largest U.S. cell tower real estate investment trusts, with materially misleading disclosures in public filings that misrepresented the contractual escalators and customer renewal assumptions underlying the company's tower lease revenue projections.
Read the full report →
Corporations — 28 June 2024 — 6 min read
The FTC charged LendingClub Bank with falsely telling borrowers they would receive the full loan amount with no hidden fees, then deducting origination fees from disbursements — leaving borrowers with substantially less money than the company had promised.
Read the full report →
Corporations — 27 June 2024 — 6 min read
Quality Systems Inc., maker of Dentrix — the dominant dental practice management platform — paid $2 million after a whistleblower alleged its software was sold to dental practices as certified for Medicaid EHR incentive programs when the deployed product did not fully meet the applicable certification criteria.
Read the full report →
Corporations — 25 June 2024 — 7 min read
The SEC examined Intellia Therapeutics' investor communications around clinical data releases for its CRISPR gene editing programs, scrutinizing whether interim trial data was characterized in ways that created materially accurate impressions of the programs' evidentiary strength and risk profile.
Read the full report →